GLP-1 prices in 2026: the self-pay programs, the new pills, and the Medicare bridge
The ways to pay for Wegovy, Zepbound and the newer GLP-1 pills changed in 2026: two oral options, manufacturer self-pay programs priced by dose, a Medicare bridge program and an announced list-price cut. Here is what changed and what it means if you pay yourself.
Updated October 15, 2026
What happened
- December 2025The FDA approved an oral form of Wegovy (semaglutide tablets) for weight management.
- February 2026Novo Nordisk announced a list-price cut for Wegovy, Ozempic and Rybelsus taking effect in January 2027, saying its self-pay prices were unaffected.
- April 2026The FDA approved orforglipron, sold as Foundayo, Eli Lilly’s daily GLP-1 pill for weight management.
- July 2026A Medicare GLP-1 bridge program began, letting eligible Part D enrollees get some obesity GLP-1s for a flat monthly copay through the end of 2027.
Three ways to pay, and which applies to you
If your commercial insurance covers a GLP-1, ask what your copay would be with the manufacturer’s savings card, subject to the card’s terms. If you are on Medicare Part D and eligible for the bridge program, its flat copay applies to the listed drugs. If you have no coverage for weight management, the manufacturers’ self-pay programs, NovoCare Pharmacy for Wegovy and Ozempic and LillyDirect for Zepbound and Foundayo, sell at published prices that depend on the dose, either shipped directly or through partner pharmacies, and TrumpRx lists offers for some of these drugs.
Where a local pharmacy fits
A local pharmacy sets its own cash price for a brand GLP-1, so compare any quote with the manufacturer’s published self-pay price for the same dose before you choose. Pharmacies also quote their own prices for generic medicines: liraglutide, the older daily GLP-1, now has generic versions, and generic diabetes medicines such as metformin, glipizide and pioglitazone are other options a prescriber may consider for blood sugar.
Compounded semaglutide and tirzepatide were sold during the shortages. With the shortages over, the FDA has tightened its position on copies of approved drugs, and it notes that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before they are marketed; our semaglutide guide sets out the position.
What to watch next
The announced list-price cut in January 2027 matters to insured patients whose deductible or coinsurance payments are based on list price, and Novo Nordisk has said it does not change its self-pay prices. Semaglutide is also among the drugs with Medicare-negotiated prices taking effect in 2027. Further oral GLP-1s are in development.
What to do
- Check whether your plan covers the drug for your diagnosis and, if so, whether you qualify for the manufacturer savings card.
- If you are on Medicare, ask whether you qualify for the GLP-1 bridge program.
- Without coverage, compare the manufacturer self-pay price for your dose with any pharmacy quote.
- Ask your prescriber whether generic liraglutide or a generic diabetes medicine would suit you.
Upload it and licensed pharmacies reply with their own cash price. You pay the pharmacy, not us.
Related
Sources
- DailyMed, FDA-approved prescribing information
- FDA, information on GLP-1 drugs and compounding
- CMS, Medicare GLP-1 Bridge
- CMS, Medicare drug price negotiation
- Novo Nordisk, US list prices for Wegovy, Ozempic and Rybelsus from January 2027 (February 24, 2026)
- NovoCare Pharmacy, self-pay Wegovy and Ozempic
- LillyDirect, Foundayo self-pay
- LillyDirect
- TrumpRx.gov
Written by the Script Unlock editorial team from the reporting and official sources above, as of October 15, 2026. Policies and prices in this area change often; check the linked sources for the latest.
Script Unlock is a marketplace that lets licensed pharmacies quote a cash price on your prescription. It does not prescribe, dispense or sell medication, does not process patient payments, and does not give medical advice. Always follow the instructions of your prescriber and pharmacist and read the medication guide supplied with your medicine.